Clinical trial
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
NCT00066781 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00066781 |
|---|---|
| Title | Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary |
| Official title | A Phase II Study Of Gemcitabine (GEMZAR) And Irinotecan (CPT-11) In Previously Untreated Patients With Measurable Disease With Unknown Primary Carcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma of Unknown Primary |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, irinotecan hydrochloride |
| Enrollment | 31 |
| Start date | Feb 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Aug 7, 2003 |
| Last update posted | Apr 4, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: